AGENUS INC AGEN revenue by segment, product and geography
In its fiscal year ending 2025-12-31, AGENUS INC reported revenue across 7 products and services; the largest, Non Cash Royalty Revenue, was $109M (+7.5% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Non Cash Royalty Revenue$109Mshare n/a+7.5% yoy
- Non Cash Revenue Related To Sale Of Future Royalties$109Mshare n/a+7.5% yoy
- Pre Commercial Product Revenue$4.24Mshare n/ano prior
- Other$1.04Mshare n/a-48.3% yoy
- Revenue$1.04Mshare n/a-48.3% yoy
- Research And Development Revenue$334Kshare n/a-30.7% yoy
- Clinical Product Revenue$334Kshare n/a-30.7% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$113M99.1%+11.5% yoy
- Outside the United States$1.04M0.9%-48.3% yoy
Members sum to the consolidated $114M for this period.
- Non Cash Royalty Revenue$29.1Mshare n/a+23.7% yoy
- Non Cash Royalty Revenue Related To The Sale Of Future Royalties$29.1Mshare n/a+23.7% yoy
- Pre Commercial Product Revenue$4.59Mshare n/ano prior
- Revenue$0share n/a-100.0% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.